arrow
H

Hugh Watkins

University of Oxford
H指数:144
被引数:11.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Left Atrial Reservoir Strain Predicts Atrial Fibrillation in Hypertrophic Cardiomyopathy

左心房储备应变预测肥厚型心肌病中的心房颤动

2025-08-220
PRE
Sex Differences in the Genetic Causes of Dilated Cardiomyopathy

扩张型心肌病的遗传病因中的性别差异

2025-07-280
PRE
Regulatory T cells attenuate chronic inflammation and cardiac fibrosis in hypertrophic cardiomyopathy

调节性T细胞减轻肥厚型心肌病的慢性炎症和心脏纤维化

2025-07-090
PRE
Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy

Aficamten 治疗:有症状性梗阻性肥厚型心肌病

2025-06-190
PRE
An ALPK3 truncation variant causing autosomal dominant hypertrophic cardiomyopathy is partially rescued by mavacamten
2025-03-240
OAAI
Protein Biomarkers of Adverse Clinical Features and Events in Sarcomeric Hypertrophic Cardiomyopathy
2024-12-011
PRE
Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4

Aficamten在症状性非梗阻性肥厚型心肌病中的疗效和安全性: 来自REDWOOD-HCM试验的结果,队列4

2024-11-017
OAAI
Considerations for drug trials in hypertrophic cardiomyopathy
2024-10-270
OAAI
Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trial

心脏生物标志物及阿非卡坦在梗阻性肥厚型心肌病中的疗效:SEQUOIA-HCM试验

2024-09-013
OAAI
Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM

Aficamten在症状性梗阻性肥厚型心肌病中的剂量和安全性: 来自sequoia-hcm的结果

2024-08-064
OAAI
A Clinical Diagnostic Test for Calcium Release Deficiency Syndrome

钙释放缺乏综合征的临床诊断试验

2024-07-162
PRE